{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T23:38:37Z","timestamp":1725579517640},"reference-count":30,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Folia Pharmacologica Japonica","Folia Pharmacol. Jpn."],"published-print":{"date-parts":[[2001]]},"DOI":"10.1254\/fpj.118.219","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T06:04:58Z","timestamp":1081836298000},"page":"219-230","source":"Crossref","is-referenced-by-count":5,"title":["Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1\/COX-2 inhibitor, to COX-2 selective inhibitors"],"prefix":"10.1254","volume":"118","author":[{"given":"Hideo","family":"NAKAMURA","sequence":"first","affiliation":[{"name":"Center of Pharmacovigilance & Regulatory Affairs, Dainippon Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"3) Katori M and Majima M: Cycloxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49, 367-392 (2000)","DOI":"10.1007\/s000110050605"},{"key":"2","unstructured":"4) Nakamura H: Neuroendocrine interactions with interleukin-1 in inflammation. In Interleukin-1, Inflammation and Disease, Edited by Bomford R and Henderson B, pp 229-241, Elsevier, Oxford (1989)"},{"key":"3","unstructured":"6) Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al: Rofecoxib [Vioxx, MK-0966; 4-(4&rsquo;-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290, 551-560 (1999)"},{"key":"4","doi-asserted-by":"crossref","unstructured":"7) Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW and Chan CC: A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45, 68-74 (1996)","DOI":"10.1007\/BF02265118"},{"key":"5","doi-asserted-by":"crossref","unstructured":"8) Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole calss of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40, 1347-1365 (1997)","DOI":"10.1021\/jm960803q"},{"key":"6","doi-asserted-by":"crossref","unstructured":"9) Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM and Geis GS: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74, 1095-1105 (1999)","DOI":"10.4065\/74.11.1095"},{"key":"7","doi-asserted-by":"crossref","unstructured":"10) Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B, for the Osteoarthritis Studies Group: Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs. A 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 9, 1124-1134 (2000)","DOI":"10.1001\/archfami.9.10.1124"},{"key":"8","doi-asserted-by":"publisher","unstructured":"11) Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, et al: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 282, 1921-1928 (1999)","DOI":"10.1001\/jama.282.20.1921"},{"key":"9","doi-asserted-by":"publisher","unstructured":"12) Emery P, Zidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC and Geis GS: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 354, 2106-2111 (1999)","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"13) McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA and FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96, 272-277 (1999)","DOI":"10.1073\/pnas.96.1.272"},{"key":"11","doi-asserted-by":"crossref","unstructured":"14) Schnitzer TJ, Truitt K, Fleischman R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg, B and Erich EW, for the Phase II Rofecoxib Rheumatoid Arthritis Study Group: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 21, 1688-1702 (1999)","DOI":"10.1016\/S0149-2918(99)80048-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"15) Ehrich EW, Dallob A, Lepeleire ID, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, Schepper PD, et al: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65, 336-347 (1999)","DOI":"10.1016\/S0009-9236(99)70113-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"16) Morrison BW, Christensen S, Yuan W, Brown J, Amlani S and Seidenberg B: Analgesic efficacy of the cycloxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 21, 943-953 (1999)","DOI":"10.1016\/S0149-2918(99)80016-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"17) Malmstrom K, Daniels S, Kotey P, Seidenberg BC and Desjardins PJ: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 21, 1653-1663 (1999)","DOI":"10.1016\/S0149-2918(99)80045-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"18) Morrison BW, Daniels SE, Kotey P, Cantu N and Seidenberg B: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 94, 504-508 (1999)","DOI":"10.1097\/00006250-199910000-00004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"19) Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, et al: Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 65, 653-660 (1999)","DOI":"10.1016\/S0009-9236(99)90087-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"20) Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342, 1946-1952 (2000)","DOI":"10.1056\/NEJM200006293422603"},{"key":"18","doi-asserted-by":"crossref","unstructured":"21) Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM and Geis SG: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95, 1681-1690 (2000)","DOI":"10.1111\/j.1572-0241.2000.02194.x"},{"key":"19","doi-asserted-by":"publisher","unstructured":"22) Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The class study: a randomized controlled trial. JAMA 284, 1247-1255 (2000)","DOI":"10.1001\/jama.284.10.1247"},{"key":"20","doi-asserted-by":"crossref","unstructured":"23) Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E and Lines CR: Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 15, 1-9 (2001)","DOI":"10.1046\/j.1365-2036.2001.00894.x"},{"key":"21","doi-asserted-by":"publisher","unstructured":"24) LangmanMJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA and Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282, 1929-1933 (1999)","DOI":"10.1001\/jama.282.20.1929"},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Bonbaridier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Daivs B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343, 1520-1528 (2000)","DOI":"10.1056\/NEJM200011233432103"},{"key":"23","doi-asserted-by":"crossref","unstructured":"26) Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM and Geis GS: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 160, 1465-1470 (2000)","DOI":"10.1001\/archinte.160.10.1465"},{"key":"24","doi-asserted-by":"crossref","unstructured":"27) McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA and FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96, 272-277 (1999)","DOI":"10.1073\/pnas.96.1.272"},{"key":"25","unstructured":"28) Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ and FitzGerald GA: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289, 735-741 (1999)"},{"key":"26","doi-asserted-by":"crossref","unstructured":"29) Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS and Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40, 124-132 (2000)","DOI":"10.1177\/00912700022008766"},{"key":"27","doi-asserted-by":"crossref","unstructured":"30) Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E and Waldman SA: A new cyclooxygenase-2 inhibitor, rofecoxib (Vioxx<SUP>&reg;<\/SUP>), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 40, 1509-1515 (2000)","DOI":"10.1177\/009127000004001224"},{"key":"28","doi-asserted-by":"crossref","unstructured":"31) Dahlen B, Szczeklik A Murray JJ: Celecoxib in patients with asthma and aspirin intolerance. N Engl J Med 344, 142 (2001)","DOI":"10.1056\/NEJM200101113440215"},{"key":"29","doi-asserted-by":"publisher","unstructured":"32) Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T and Kasuga M: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific entagonist delays healing in mice. Gastroenterology 112, 387-397 (1997)","DOI":"10.1053\/gast.1997.v112.pm9024292"},{"key":"30","doi-asserted-by":"crossref","unstructured":"33) Schmassmann A: Mechanisms of ulcer healing and efects of nonsteroidal anti-inflammatory drugs. Am J Med 104 (3A), 43S-51S (1998)","DOI":"10.1016\/S0002-9343(97)00211-8"}],"container-title":["Folia Pharmacologica Japonica"],"original-title":["\u30b7\u30af\u30ed\u30aa\u30ad\u30b7\u30b2\u30ca\u30fc\u30bc (COX)-2\u9078\u629e\u7684\u963b\u5bb3\u85ac:"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fpj\/118\/3\/118_3_219\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T07:32:51Z","timestamp":1682667171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fpj\/118\/3\/118_3_219\/_article\/-char\/ja\/"}},"subtitle":["\u30a2\u30b9\u30d4\u30ea\u30f3,COX-1\/COX-2\u963b\u5bb3\u85ac\u304b\u3089COX-2\u9078\u629e\u7684\u963b\u5bb3\u85ac\u3078"],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001]]}},"URL":"https:\/\/doi.org\/10.1254\/fpj.118.219","relation":{},"ISSN":["0015-5691","1347-8397"],"issn-type":[{"value":"0015-5691","type":"print"},{"value":"1347-8397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001]]}}}